The Vanderbilt-Ingram Cancer Center SPORE in GI Cancer is committed to innovative translational research to reduce and prevent colorectal cancers. The GI SPORE interdisciplinary team consists of clinical and basic science investigators with expertise in genetics, cellular and molecular biology, pathology, medical, surgical and radiation oncology, clinical trial design, epidemiology, mass spectrometry, biostatistics and biomedical informatics.
The goal of the GI SPORE is to apply the translational research strengths of Vanderbilt University toward reducing the incidence, morbidity and mortality of colorectal cancer.
The objectives of the GI SPORE include:
- Translate discoveries in EGF receptor (EGFR) biology into improved therapies for patients with colorectal cancer;
- Develop and use biological assays for a high throughput screen to identify antagonists of canonical unit signaling and drugs that restore cell surface E-cadherin;
- Understand and control genetic and epigenetic changes in colorectal tumors that lead to malignancy with a special emphasis on p120;
- Identify biomarkers to assess individual risk for developing colorectal neoplasia.
The SPORE in GI Cancer Team
- Robert J. Coffey, M.D., Program Director
- Jordan D. Berlin, M.D., Co-Director
- R. Daniel Beauchamp, M.D.
- Ethan Lee, M.D., Ph.D.
- Mary Kay Washington, M.D., Ph.D.
- Albert B. Reynolds, Ph.D.
- Reid M. Ness, M.D., M.P.H.
- Wei Zheng, M.D., Ph.D.
- Martha J. Shrubsole, Ph.D.
- Yu Shyr, Ph.D.
- Charles D. Weaver, Ph.D.
- Nipun B. Merchant, M.D.
For more information about the SPORE program, see NCI's SPORE website.